|
Fusion gene ID: 42310 |
FusionGeneSummary for YEATS2_PRKCI |
Fusion gene summary |
Fusion gene information | Fusion gene name: YEATS2_PRKCI | Fusion gene ID: 42310 | Hgene | Tgene | Gene symbol | YEATS2 | PRKCI | Gene ID | 55689 | 5584 |
Gene name | YEATS domain containing 2 | protein kinase C iota | |
Synonyms | - | DXS1179E|PKCI|nPKC-iota | |
Cytomap | 3q27.1 | 3q26.2 | |
Type of gene | protein-coding | protein-coding | |
Description | YEATS domain-containing protein 2 | protein kinase C iota typePRKC-lambda/iotaaPKC-lambda/iotaatypical protein kinase C-lambda/iota | |
Modification date | 20180519 | 20180523 | |
UniProtAcc | Q9ULM3 | P41743 | |
Ensembl transtripts involved in fusion gene | ENST00000305135, | ENST00000295797, | |
Fusion gene scores | * DoF score | 11 X 7 X 6=462 | 6 X 6 X 6=216 |
# samples | 11 | 6 | |
** MAII score | log2(11/462*10)=-2.0703893278914 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(6/216*10)=-1.84799690655495 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: YEATS2 [Title/Abstract] AND PRKCI [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | YEATS2 | GO:0000122 | negative regulation of transcription by RNA polymerase II | 18838386 |
Hgene | YEATS2 | GO:0043966 | histone H3 acetylation | 18838386 |
Hgene | YEATS2 | GO:0045892 | negative regulation of transcription, DNA-templated | 18838386 |
Tgene | PRKCI | GO:0006468 | protein phosphorylation | 8226978 |
Tgene | PRKCI | GO:0018105 | peptidyl-serine phosphorylation | 21983565 |
Tgene | PRKCI | GO:0043524 | negative regulation of neuron apoptotic process | 10467349 |
Tgene | PRKCI | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 10467349 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | LD | KIRP | TCGA-G7-6793-01A | YEATS2 | chr3 | 183415781 | + | PRKCI | chr3 | 169953018 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5UTR-3CDS | ENST00000305135 | ENST00000295797 | YEATS2 | chr3 | 183415781 | + | PRKCI | chr3 | 169953018 | + |
Top |
FusionProtFeatures for YEATS2_PRKCI |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
YEATS2 | PRKCI |
Chromatin reader component of the ATAC complex, acomplex with histone acetyltransferase activity on histones H3 andH4. YEATS2 specifically recognizes and binds histone H3crotonylated at 'Lys-27' (H3K27cr) (PubMed:27103431).Crotonylation marks active promoters and enhancers and confersresistance to transcriptional repressors (PubMed:27103431).{ECO:0000269|PubMed:18838386, ECO:0000269|PubMed:19103755,ECO:0000269|PubMed:27103431}. | Calcium- and diacylglycerol-independent serine/threonine-protein kinase that plays a general protective roleagainst apoptotic stimuli, is involved in NF-kappa-B activation,cell survival, differentiation and polarity, and contributes tothe regulation of microtubule dynamics in the early secretorypathway. Is necessary for BCR-ABL oncogene-mediated resistance toapoptotic drug in leukemia cells, protecting leukemia cellsagainst drug-induced apoptosis. In cultured neurons, preventsamyloid beta protein-induced apoptosis by interrupting cell deathprocess at a very early step. In glioblastoma cells, may functiondownstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 inthe promotion of cell survival by phosphorylating and inhibitingthe pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 andregulate ECT2 oncogenic activity by phosphorylation, which in turnpromotes transformed growth and invasion. In response to nervegrowth factor (NGF), acts downstream of SRC to phosphorylate andactivate IRAK1, allowing the subsequent activation of NF-kappa-Band neuronal cell survival. Functions in the organization of theapical domain in epithelial cells by phosphorylating EZR. Thisstep is crucial for activation and normal distribution of EZR atthe early stages of intestinal epithelial cell differentiation.Forms a protein complex with LLGL1 and PARD6B independently ofPARD3 to regulate epithelial cell polarity. Plays a role inmicrotubule dynamics in the early secretory pathway throughinteraction with RAB2A and GAPDH and recruitment to vesiculartubular clusters (VTCs). In human coronary artery endothelialcells (HCAEC), is activated by saturated fatty acids and mediateslipid-induced apoptosis. {ECO:0000269|PubMed:10356400,ECO:0000269|PubMed:10467349, ECO:0000269|PubMed:10906326,ECO:0000269|PubMed:11042363, ECO:0000269|PubMed:11724794,ECO:0000269|PubMed:12871960, ECO:0000269|PubMed:14684752,ECO:0000269|PubMed:15994303, ECO:0000269|PubMed:18270268,ECO:0000269|PubMed:19327373, ECO:0000269|PubMed:21189248,ECO:0000269|PubMed:21419810, ECO:0000269|PubMed:8226978,ECO:0000269|PubMed:9346882}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for YEATS2_PRKCI |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for YEATS2_PRKCI |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
YEATS2 | RAD21, TFAP4, ZZZ3, UBAP2L, CSRP2BP, KAT2A, KAT2B, MAP3K7, TADA3, TADA2A, MBIP, WDR5, CCDC101, DR1, POLE3, POLE4, SNRNP200, NXF1, MAGEA10, PSME3, RFPL4B, BCAT1, TSSC1, CARD8, PSMC3, TBP, CEP162, CEP120, CDK2, CDC23, NANOG, POU5F1, IKZF5, SPERT, CDH19, LMO2, CCBL1, TP53INP1, IL17RA, TRIM25, TXNIP | PRKCI | PDPK1, PARD6A, BAD, ADAP1, YWHAZ, RAB4A, SQSTM1, SMG1, GAPDH, PARD3, FRS2, USP21, MARK2, GABARAPL1, GABARAPL2, MAP1LC3A, MAP1LC3B, SFPQ, VHL, CHUK, IKBKB, DUSP1, YWHAH, MARK4, PARD6B, PARD6G, GBAS, LLGL1, HSP90AA1, LLGL2, CDC37, NIPSNAP1, RAPGEF2, MYO10, PNMA1, FABP4, TTR, TSC22D1, MBP, CDK7, ELAVL1, TJP1, ARHGAP17, MAP2K5, APP, YWHAE, GAB1, NPM1, CRX, CASP8, IL1RAP, IKBKG, AMOT, PRKCZ, RHOJ, RASSF8, KIF23, PPM1A, PPM1B, CEP135, TMEM17, XPO1, SSB, MAGED2, ZNF609, TMEM208, EIF4ENIF1, TRAPPC13, MASTL, SMURF1, MTMR4, FYN, NGEF, KBTBD7, GPR156, FARP2, CD44, FGB, ARHGEF16, KERA, PDGFD, UBC, DCAF7, TRIM25, WWC1 |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for YEATS2_PRKCI |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for YEATS2_PRKCI |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | PRKCI | C0005586 | Bipolar Disorder | 2 | PSYGENET |
Tgene | PRKCI | C0011570 | Mental Depression | 1 | PSYGENET |
Tgene | PRKCI | C0011581 | Depressive disorder | 1 | PSYGENET |